Clonidine suspensions to attenuate opioid withdrawal symptoms in children require low doses and dilute concentrations.
× 150 mm column (Waters Corporation; lot 0180333231061), XTerra C18 3.9 × 20 mm guard column (Waters Corporation; lot 0180333261), and ultraviolet dual-absorbance detector (model 2487; Waters Alliance System), set at 205 nm. The mobile-phase gradient consisted of 33%-55%-33% acetonitrile (Fisher Scientific; lot 136170) and 67%-45%-67% 10 mmol/L ammonium formate buffer (Sigma-Aldrich; lot BCBJ-6906V) at pH 10.0 and 25°C. All solvents were HPLC-grade and filtered. The flow rate was 1.0 mL/min. Assay and degradation methods were developed in the authors' laboratory on the basis of previous work.
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The calibration curve (0.0010, 0.0014, 0.0018, 0.0022, 0.0026, and 0.0028 mg/mL) encompassed diluted test concentrations of clonidine (nominally 0.0020 mg/mL) and was generated by least-squares regression of the peak area ratio of clonidine to lidocaine and the concentration of each clonidine standard. Acceptable coefficients of variation for precision were defined as less than 10% and the limits for accuracy as greater than 90%.
On the day of analysis, each study sample (nominal concentration 0.010 mg/mL) was thawed and vortex-mixed for 10 s. A 0.400-mL aliquot was diluted with 0.600 mL of HPLC-grade water and centrifuged at 5200 rpm for 5 min. Then, 0.500 mL of supernatant was mixed with 0.100 mL of lidocaine (0.050 mg/mL) and the volume was adjusted to 1 mL with HPLC-grade water, with final nominal concentrations 0.0020 mg/mL (clonidine) and 0.0050 mg/mL (lidocaine). Each sample was filtered via 0.45-µm Acrodisc microfilter (Waters Corporation; lot 21829235) before injection (75-µL) onto the column.
Accelerated degradation of clonidine was achieved as follows. Clonidine suspensions (0.0010 mg/mL) in Oral Mix and Oral Mix SF were prepared (without internal standard) from stock solution (0.020 mg/mL). Aliquots were mixed (v/v) with 2N sodium hydroxide, 2N hydrochloric acid, or 30% hydrogen peroxide, then vortex-mixed and incubated for 2 h at 90°C. Samples were cooled to room temperature, pH was adjusted to 4.5, and concentration was adjusted with HPLC-grade water to 0.0020 mg/mL. Samples were filtered and injected onto the column.
Regression analysis demonstrated linearity, with r 2 of 0.996 or above (n = 4). Intraday and interday coefficients of variation were 1.80% and 4.47%, respectively, for the 0.0010 mg/mL solution; 2.15% and 3.02%, respectively, for the 0.0016 mg/mL solution; 1.36% and 1.59%, respectively, for the 0.0020 mg/mL solution; and 2.25% and 1.35%, respectively, for the 0.0028 mg/mL solution. Mean intraday and interday accuracies (± standard deviation) were 96.12% ± 2.86% and 96.12% ± 3.26%, respectively, for the 0.0010 mg/mL solution; 97.26% ± 2.13% and 98.50% ± 1.74%, respectively, for the 0.0016 mg/mL solution; 97.73% ± 0.82% and 98.43% ± 1.60%, respectively, for the 0.0020 mg/mL solution; and 98.52% ± 1.15% and 98.80% ± 0.96%, respectively, for the 0.0028 mg/mL solution. Retention times were 4.99 min (clonidine) and 9.11 min (lidocaine). No interfering peaks were generated by forced degradation of clonidine. Clonidine peaks decreased by 26%, on average, and minor degradation peaks appeared at 4.36, 5.57, and 9.30 min.
Throughout the study period, the mean pH ranged from 4.82 to 4.89 for suspensions in Oral Mix and from 5.00 to 5.06 for suspensions in Oral Mix SF. All suspensions were easily resuspended, with no notable changes in the milky white colour; the faint, tart cherry taste; or odour.
HPLC analysis showed that all suspensions maintained more than 94% of the original concentration for 91 days (Tables 1 and 2 ).
In conclusion, clonidine suspensions (0.010 mg/mL) in Oral Mix and Oral Mix SF stored in amber glass bottles, plastic bottles, or oral plastic syringes at 25°C or in amber glass or plastic bottles at 4°C can be expected to remain stable for up to 91 days.
